Company Overview and News

 
Duketon Mining extends strike length at Golden Star in Eastern Yilgarn province

2018-04-19 proactiveinvestors.com.au
Duketon Mining Ltd (ASX:DKM) has released assay results for the Golden Star prospect in Western Australia, boosting management’s confidence that it is on to a larger gold zone.
DKM RRL SBM RGRNF GSC

 
St Barbara takes 12.3% stake in Duketon Mining

2018-04-05 australianmining.com.au
Australian gold exploration and production company St Barbara has paid $4 million for 14.5 million shares of Duketon Mining at a price of 27.5 cents per share, representing a 12.3 per cent investment in the company.
DKM CYL SBM ABMMF SMP PEX ABU

 
Resolute, St Barbara invest $9m in junior explorers

2018-04-04 businessnews.com.au
Gold miner St Barbara has invested $4 million in local explorer Duketon Mining, while Resolute Mining has announced it will take a $5.1 million stake in a Canadian gold-focused company.
RSG DKM RMGGY RMGGF SBM

 
Duketon Mining surges after St Barbara Ltd’s $4 million investment in gold-nickel strategy

2018-04-04 proactiveinvestors.com.au
Duketon Mining Ltd (ASX:DKM) has surged to a new 12-month high of 30 cents on news of a $4 million investment by mid-tier gold producer St Barbara Ltd (ASX:SBM).
DKM CYL SBM ABMMF PEX ABU

 
Gold miners invest $9m

2018-04-04 businessnews.com.au
Gold miner St Barbara has invested $4 million in local explorer Duketon Mining, while Resolute Mining has announced it will take a $5.1 million stake in a Canadian gold-focused company.
RSG DKM RMGGY RMGGF SBM

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...